• 1
    Camilleri M. Management of the irritable bowel syndrome. Gastroenterology 2001; 120: 65268.
  • 2
    Bouin M, Plourde V, Boivin M, et al. Rectal distention testing in patients with irritable bowel syndrome: sensitivity, specificity, and predictive values of pain sensory thresholds. Gastroenterology 2002; 122: 17717.
  • 3
    Kuiken SD, Lindeboom R, Tytgat GN, Boeckxstaens GE. Relationship between symptoms and hypersensitivity to rectal distension in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2005; 22: 15764.
  • 4
    Mertz H, Naliboff B, Munakata J, Niazi N, Mayer EA. Altered rectal perception is a biological marker of patients with irritable bowel syndrome. Gastroenterology 1995; 109: 4052.
  • 5
    Munakata J, Naliboff B, Harraf F, et al. Repetitive sigmoid stimulation induces rectal hyperalgesia in patients with irritable bowel syndrome. Gastroenterology 1997; 112: 5563.
  • 6
    Mertz H. Review article: visceral hypersensitivity. Aliment Pharmacol Ther 2003; 17: 62333.
  • 7
    Mayer EA, Gebhart GF. Basic and clinical aspects of visceral hyperalgesia. Gastroenterology 1994; 107: 27193.
  • 8
    Cervero F, Laird JM. Visceral pain. Lancet 1999; 353: 21458.
  • 9
    Bueno L, Fioramonti J, Delvaux M, Frexinos J. Mediators and pharmacology of visceral sensitivity: from basic to clinical investigations. Gastroenterology 1997; 112: 171443.
  • 10
    Plourde V, Lembo T, Shui Z, et al. Effects of the somatostatin analogue octreotide on rectal afferent nerves in humans. Am J Physiol 1993; 265: G74251.
  • 11
    Chey WD, Beydoun A, Roberts DJ, Hasler WL, Owyang C. Octreotide reduces perception of rectal electrical stimulation by spinal afferent pathway inhibition. Am J Physiol 1995; 269: G8216.
  • 12
    Mertz H, Walsh JH, Sytnik B, Mayer EA. The effect of octreotide on human gastric compliance and sensory perception. Neurogastroenterol Motil 1995; 7: 17585.
  • 13
    Foxx-Orenstein A, Camilleri M, Stephens D, Burton D. Effect of a somatostatin analogue on gastric motor and sensory functions in healthy humans. Gut 2003; 52: 155561.
  • 14
    Schwetz I, Naliboff B, Munakata J, et al. Anti-hyperalgesic effect of octreotide in patients with irritable bowel syndrome. Aliment Pharmacol Ther 2004; 19: 12331.
  • 15
    Bradette M, Delvaux M, Staumont G, Fioramonti J, Bueno L, Frexinos J. Octreotide increases thresholds of colonic visceral perception in IBS patients without modifying muscle tone. Dig Dis Sci 1994; 39: 11718.
  • 16
    Hasler WL, Soudah HC, Owyang C. Somatostatin analog inhibits afferent response to rectal distention in diarrhea-predominant irritable bowel patients. J Pharmacol Exp Ther 1994; 268: 120611.
  • 17
    Dueno MI, Bai JC, Santangelo WC, Krejs GJ. Effect of somatostatin analog on water and electrolyte transport and transit time in human small bowel. Dig Dis Sci 1987; 32: 10926.
  • 18
    Freda PU. Somatostatin analogs in acromegaly. J Clin Endocrinol Metab 2002; 87: 30138.
  • 19
    Harris AG, O’Dorisio TM, Woltering EA, et al. Consensus statement: octreotide dose titration in secretory diarrhea. Diarrhea Management Consensus Development Panel. Dig Dis Sci 1995; 40: 146473.
  • 20
    Lamberts SW, Van Der Lely AJ, De Herder WW, Hofland LJ. Octreotide N Engl J Med 1996; 334: 24654.
  • 21
    Talley NJ, Turner I, Middleton WR. Somatostatin and symptomatic relief of irritable bowel syndrome. Lancet 1987; 2: 1144.
  • 22
    Thompson WG, Longstreth GF, Drossman DA, Heaton KW, Irvine EJ, Muller-Lissner SA. Functional bowel disorders and functional abdominal pain. Gut 1999; 45(Suppl. 2): II437.
  • 23
    Kuiken SD, Tytgat GN, Boeckxstaens GE. The selective serotonin reuptake inhibitor fluoxetine does not change rectal sensitivity and symptoms in patients with irritable bowel syndrome: a double blind, randomized, placebo-controlled study. Clin Gastroenterol Hepatol 2003; 1: 21928.
  • 24
    Muller-Lissner SA, Fumagalli I, Bardhan KD, et al. Tegaserod, a 5-HT(4) receptor partial agonist, relieves symptoms in irritable bowel syndrome patients with abdominal pain, bloating and constipation. Aliment Pharmacol Ther 2001; 15: 165566.
  • 25
    Svedlund J, Sjodin I, Dotevall G. GSRS – a clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig Dis Sci 1988; 33: 12934.
  • 26
    Kuiken SD, Klooker TK, Tytgat GN, Lei A, Boeckxstaens GE. Possible role of nitric oxide in visceral hypersensitivity in patients with irritable bowel syndrome. Neurogastroenterol Motil 2006; 18: 11522.
  • 27
    Tulassay Z. Somatostatin and the gastrointestinal tract. Scand J Gastroenterol Suppl 1998; 228: 11521.
  • 28
    Patel YC, Greenwood MT, Panetta R, Demchyshyn L, Niznik H, Srikant CB. The somatostatin receptor family. Life Sci 1995; 57: 124965.
  • 29
    Moller LN, Stidsen CE, Hartmann B, Holst JJ. Somatostatin receptors. Biochim Biophys Acta 2003; 1616: 184.
  • 30
    Taniyama Y, Suzuki T, Mikami Y, Moriya T, Satomi S, Sasano H. Systemic distribution of somatostatin receptor subtypes in human: an immunohistochemical study. Endocr J 2005; 52: 60511.
  • 31
    Taura P, Planella V, Balust J, et al. Epidural somatostatin as an analgesic in upper abdominal surgery: a double-blind study. Pain 1994; 59: 13540.
  • 32
    Carlton SM, Zhou S, Du J, Hargett GL, Ji G, Coggeshall RE. Somatostatin modulates the transient receptor potential vanilloid 1 (TRPV1) ion channel. Pain 2004; 110: 61627.
  • 33
    Johnston BT, Shils J, Leite LP, Castell DO. Effects of octreotide on esophageal visceral perception and cerebral evoked potentials induced by balloon distension. Am J Gastroenterol 1999; 94: 6570.
    Direct Link:
  • 34
    Hukovic N, Panetta R, Kumar U, Patel YC. Agonist-dependent regulation of cloned human somatostatin receptor types 1-5 (hSSTR1-5): subtype selective internalization or upregulation. Endocrinology 1996; 137: 40469.
  • 35
    Kuiken SD, Vergeer M, Heisterkamp SH, Tytgat GN, Boeckxstaens GE. Role of nitric oxide in gastric motor and sensory functions in healthy subjects. Gut 2002; 51: 2128.
  • 36
    Spiller R. Pharmacotherapy: non-serotonergic mechanisms. Gut 2002; 51(Suppl. 1): i8790.
  • 37
    Cozzi R, Attanasio R, Montini M, et al. Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? J Clin Endocrinol Metab 2003; 88: 30908.
  • 38
    Chen T, Miller TF, Prasad P, et al. Pharmacokinetics, pharmacodynamics, and safety of microencapsulated octreotide acetate in healthy subjects. J Clin Pharmacol 2000; 40: 47581.
  • 39
    Newman CB, Melmed S, Snyder PJ, et al. Safety and efficacy of long-term octreotide therapy of acromegaly: results of a multicenter trial in 103 patients–a clinical research center study. J Clin Endocrinol Metab 1995; 80: 276875.
  • 40
    Woltering EA, Mamikunian PM, Zietz S, et al. Effect of octreotide LAR dose and weight on octreotide blood levels in patients with neuroendocrine tumors. Pancreas 2005; 31: 392400.
  • 41
    Chrubasik J, Meynadier J, Blond S, et al. Somatostatin, a potent analgesic. Lancet 1984; 2: 12089.
  • 42
    Paice JA, Penn RD, Kroin JS. Intrathecal octreotide for relief of intractable nonmalignant pain: 5-year experience with two cases. Neurosurgery 1996; 38: 2037.
  • 43
    Penn RD, Paice JA, Kroin JS. Octreotide: a potent new non-opiate analgesic for intrathecal infusion. Pain 1992; 49: 139.
  • 44
    Su X, Burton MB, Gebhart GF. Effects of octreotide on responses to colorectal distension in the rat. Gut 2001; 48: 67682.
  • 45
    Park C, Yang I, Woo J, et al. Somatostatin (SRIF) receptor subtype 2 and 5 gene expression in growth hormone-secreting pituitary adenomas: the relationship with endogenous srif activity and response to octreotide. Endocr J 2004; 51: 22736.